In patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (HCT), adding radioimmunotherapy to the standard BEAM conditioning regimen provides no clinical benefit, according to results from a randomized phase III clinical trial conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Two-year progression-free survival, the primary end point in the study, was comparable in the BEAM group (n=111) and the BEAM plus rituximab group (n=113): 47.9% vs. 48.6%, respectively (p=0.94). The authors noted that the only variable predictive of an improved overall survival was the documentation of a complete response of the DLBCL before the transplantation procedure.
No Clinical Benefit in Adding Radioimmunotherapy to BEAM Conditioning in Autologous HCT for Relapsed DLBCL
Mar 2013